Monopar Therapeutics Inc logo

Monopar Therapeutics Inc

NAS:MNPR (USA)  
$ 22.05 -1.95 (-8.13%) 01:00 PM EST
At Loss
P/B:
17.14
Market Cap:
$ 126.67M
Enterprise V:
$ 127.95M
Volume:
21.46K
Avg Vol (2M):
724.67K
Trade In:
Volume:
21.46K
At Loss
Avg Vol (2M):
724.67K

Business Description

Description
Monopar Therapeutics Inc is a clinical-stage biopharmaceutical company focused on developing proprietary therapeutics designed to extend life or improve the quality of life for cancer patients. The company's pipeline consists of?Validive?for the prevention of chemoradiotherapy-induced severe oral mucositis in oropharyngeal cancer patients, camsirubicin?for the treatment?of soft tissue sarcoma, a late-stage preclinical antibody, MNPR-101, for cancers and severe COVID-19 and an early-stage camsirubicin analog, MNPR-202, for various cancers.
Name Current Vs Industry Vs History
Cash-To-Debt No Debt
Equity-to-Asset 0.82
Interest Coverage No Debt
Piotroski F-Score 3/9
0
1
2
3
4
5
6
7
8
9
WACC vs ROIC
WACC
ROIC
Name Current Vs Industry Vs History
5-Day RSI 41.98
9-Day RSI 49.28
14-Day RSI 53.5
6-1 Month Momentum % 482.44
12-1 Month Momentum % 909.54

Liquidity Ratio

Name Current Vs Industry Vs History
Current Ratio 5.41
Quick Ratio 5.41
Cash Ratio 5.36

Dividend & Buy Back

Name Current Vs Industry Vs History
3-Year Average Share Buyback Ratio -9.2
Shareholder Yield % -2.61
Name Current Vs Industry Vs History
ROE % -105.4
ROA % -84.96
ROIC % -27996
ROC (Joel Greenblatt) % -27996
ROCE % -113.94

Financials (Next Earnings Date:2025-03-28 Est.)

MNPR's 30-Y Financials
Income Statement Breakdown FY
No Enough Data
Balance Sheet Breakdown
No Enough Data
Cashflow Statement Breakdown
No Enough Data

Historical Operating Revenue by Business Segment

Historical Operating Revenue by Geographic Region

5-Step DuPont Analysis as of
No Enough Data

Guru Trades

See Details
To

Insider Trades

See Details
To

Gurus Latest Trades with NAS:MNPR

No Available Data

Peter Lynch Chart

Y-axis scale:
Interactive Chart
To

Performance

Dividend
Log
Bar
To

Annualized Return %  

Symbol
1 Week
1 Month
3 Months
6 Months
YTD
1 Year
3 Years
5 Years
10 Years

Total Annual Return %  

Symbol
2024
2023
2022
2021
2020
2019
2018
2017
2016
2015

Monopar Therapeutics Inc Executives

Details

GF Value

Valuation Chart

Year:

Analyst Estimate

Key Statistics

Name Value
Revenue (TTM) (Mil $)
EPS (TTM) ($) -1.99
Beta 1.55
Volatility % 244.75
14-Day RSI 53.5
14-Day ATR ($) 3.271195
20-Day SMA ($) 23.7085
12-1 Month Momentum % 909.54
52-Week Range ($) 1.545 - 38.5
Shares Outstanding (Mil) 5.28

Piotroski F-Score Details

Year:
Component Result
Piotroski F-Score 3
Positive ROA
Positive CFROA
Higher ROA yoy
CFROA > ROA
Lower Leverage yoy
Higher Current Ratio yoy
Less Shares Outstanding yoy
Higher Gross Margin yoy
Higher Asset Turnover yoy

Monopar Therapeutics Inc Filings

Filing Date Document Date Form
No Filing Data

Monopar Therapeutics Inc Stock Events

Financials Calendars
Event Date Price($)
No Event Data

Monopar Therapeutics Inc Frequently Asked Questions

What is Monopar Therapeutics Inc(MNPR)'s stock price today?
The current price of MNPR is $22.05. The 52 week high of MNPR is $38.50 and 52 week low is $1.55.
When is next earnings date of Monopar Therapeutics Inc(MNPR)?
The next earnings date of Monopar Therapeutics Inc(MNPR) is 2025-03-28 Est..
Does Monopar Therapeutics Inc(MNPR) pay dividends? If so, how much?
Monopar Therapeutics Inc(MNPR) does not pay dividend.

Press Release

Subject Date
No Press Release

Headlines

See More
  • 1
No news.
  • 1